Notice for capmatinib (as hydrochloride) (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
capmatinib (as hydrochloride)
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet
Indication
Treatment of non-small cell lung cancer (NSCLC) with genetic MET alterations
Therapeutic area
Oncology